NAFLD and type 2 diabetes: A practical guide for the joint management
Gastroenterol Hepatol. 2023 Dec;46(10):815-825.
doi: 10.1016/j.gastrohep.2022.12.002.
Epub 2022 Dec 27.
[Article in
English,
Spanish]
Affiliations
- 1 Endocrinology and Nutrition Department, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona (UAB), Barcelona, Spain; Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), Barcelona, Spain.
- 2 Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, Santander, Spain.
- 3 Endocrinology and Nutrition Department, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona (UAB), Barcelona, Spain; Diabetes and Associated Metabolic Diseases CIBER (CIBERDEM), Spain. Electronic address: aperez@santpau.cat.
- 4 Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, Santander, Spain. Electronic address: javiercrespo1991@gmail.com.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is becoming a major cause of liver disease-related morbidity, as well as mortality. Importantly, NAFLD is considered a mediator of systemic diseases including cardiovascular disease. Its prevalence is expected to increase, mainly due to its close association with obesity and type 2 diabetes mellitus (T2D). In addition, T2D and NAFLD share common pathophysiological mechanisms, and one can lead to or worsen the other. Therefore, a close collaboration between primary care physician, endocrinologists and hepatologists is essential to optimize the management of patients with NAFLD and T2D. Here, we summarize relevant aspects about NAFLD and T2D that all clinician managing these patients should know as well as current therapeutic options for the treatment of T2D associated with NAFLD.
Keywords:
Agonistas del receptor del péptido similar al glucagón tipo 1; Cribado de fibrosis hepática; Diabetes mellitus tipo 2; Esteatosis hepática metabólica; Fibrosis screening; Glucagon-like peptide-1 receptor agonists; Non-alcoholic fatty liver disease; Pioglitazona; Pioglitazone; Type 2 diabetes mellitus.
Copyright © 2022 Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Diabetes Mellitus, Type 2* / complications
-
Diabetes Mellitus, Type 2* / therapy
-
Humans
-
Non-alcoholic Fatty Liver Disease* / complications
-
Non-alcoholic Fatty Liver Disease* / therapy
-
Obesity / complications